Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome
The current study underscores the significance of achieving ≥50% LDL-C reduction in addition to a target of 55 mg/dL in preventing additional cardiovascular events in ACS patients.
Authors
- Mariko Harada‐Shiba (ORCID: https://orcid.org/0000-0002-7600-2059)
- Masaaki Hoshiga
- Yohei Yamauchi
- Hirofumi Kusumoto (ORCID: https://orcid.org/0000-0001-8721-7680)
- Shimpei Fujioka (ORCID: https://orcid.org/0000-0002-1132-3564)
- Kensaku Shibata
- Hideaki Morita (ORCID: https://orcid.org/0000-0002-4638-7752)
- Kazushi Sakane (ORCID: https://orcid.org/0000-0003-2386-6926)
- Yumiko Kanzaki (ORCID: https://orcid.org/0000-0003-1228-1201)
- Masahito Michikura (ORCID: https://orcid.org/0000-0002-1258-8310)
- Tomohiro Fujisaka
- Daisuke Shishikura
Institutions
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Journal of clinical lipidology
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1016/j.jacl.2024.10.010
- Citations
- 3
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- Amgen
- Medpace
- Kowa Company